𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Risk of Cardiac Valve Regurgitation with Dopamine Agonist use in Parkinson’s Disease and Hyperprolactinaemia

✍ Scribed by Dr Gianluca Trifirò, M. Mostafa Mokhles, Jeanne P. Dieleman, Eva M. van Soest, Katia Verhamme, Giampiero Mazzaglia, Ron Herings, Cynthia de Luise, Douglas Ross, Guy Brusselle, Annamaria Colao, Wilhelm Haverkamp, Rene chade, Guy van Camp, Renzo Zanettini, et al

Book ID
119931277
Publisher
Springer International Publishing AG
Year
2012
Tongue
English
Weight
170 KB
Volume
35
Category
Article
ISSN
0114-5916

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The risk of valvular regurgitation in pa
The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists
✍ Vibeke Guldbrand Rasmussen; Karen Østergaard; Erik Dupont; Steen Hvitfeldt Pouls 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB 👁 1 views

## Abstract ## Objectives: Several observational studies suggest an association between treatment with ergoline‐derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta‐analysis. ## Methods: Observational studies addressin

Meta-analysis of heart valve abnormaliti
Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists
✍ Gregor Simonis; Joerg T. Fuhrmann; Ruth H. Strasser 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

## Abstract Valvular heart disease in patients being treated with ergot‐derivative dopamine agonists (Ergot‐DA) for Parkinson's disease has been reported to occur as a consequence of serotonine receptor stimulation. Goal of this analysis was to estimate the incidence of those changes from recently